Table 2
Predicted observed survival proportions by diagnostic group and selected subgroup, selected survival durations, ages 0 to 14 at diagnosis, Canada excluding Quebec, 2013 to 2017


Table 2
Predicted observed survival proportions by diagnostic group and selected subgroup, selected survival durations, ages 0 to 14 at diagnosis, Canada excluding Quebec, 2013 to 2017
Table summary
This table displays the results of Predicted observed survival proportions by diagnostic group and selected subgroup. The information is grouped by Diagnostic group / subgroup (appearing as row headers), Survival duration, OSP (%), 1 year, 3 years, 5 years, 10 years and 95% CI (appearing as column headers).
Diagnostic group / subgroup Survival duration
OSP (%) 1 year OSP (%) 3 years OSP (%) 5 years OSP (%) 10 years
95% CI 95% CI 95% CI 95% CI
from to from to from to from to
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 95 93 96 89 88 91 88 87 90 87 85 89
a. Lymphoid leukemias 97 96 98 94 92 95 93 92 95 92 90 94
b. Acute myeloid leukemias 81 74 86 66 59 73 65 57 71 63 55 69
c. Chronic myeloproliferative diseases 97 87 99 93 83 97 90 79 95 86 73 93
II. Lymphomas and reticuloendothelial neoplasms 96 94 97 94 91 96 92 89 94 90 88 93
a. Hodgkin lymphomas 99 95 100 99 95 100 99 95 100 99 95 100
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 93 89 96 88 82 92 84 78 89 80 74 86
c. Burkitt lymphoma 97 89 99 96 87 99 94 84 98 94 84 98
d. Miscellaneous lymphoreticular neoplasms 96 90 98 95 89 98 94 88 97 94 88 97
III. CNS and miscellaneous intracranial and intraspinal neoplasms 84 81 87 75 71 78 72 69 75 69 66 72
a. Ependymomas and choroid plexus tumour 96 88 99 84 74 91 78 67 86 68Note E: Use with caution 56 78
b. Astrocytomas 88 84 91 83 78 87 82 78 86 82 77 85
c. Intracranial and intraspinal embryonal tumours 85 79 90 75 68 81 71 64 78 66 58 73
d. Other gliomas 64 54 72 44 34 53 42 33 51 40 31 49
IV. Neuroblastoma and other peripheral nervous cell tumours 96 92 97 90 85 93 84 79 88 80 75 85
a. Neuroblastoma and ganglioneuroblastoma 95 92 97 89 85 93 84 79 88 80 75 85
V. Retinoblastoma 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 94 85 98 94 85 98 93 84 97
VI. Renal tumours 98 95 99 96 92 98 96 91 98 94 89 96
a. Nephroblastoma and other nonepithelial renal tumours 98 95 99 97 92 98 96 92 98 95 90 97
VII. Hepatic tumours 84Note E: Use with caution 71 92 72Note E: Use with caution 58 82 72Note E: Use with caution 58 82 72Note E: Use with caution 58 82
VIII. Malignant bone tumours 97 92 99 76 68 82 72 64 78 67 59 74
a. Osteosarcomas 95 87 98 70Note E: Use with caution 59 79 65Note E: Use with caution 53 74 59Note E: Use with caution 48 69
c. Ewing tumour and related sarcomas of bone 98 88 100 82 70 90 79Note E: Use with caution 66 87 75Note E: Use with caution 62 84
IX. Soft tissue and other extraosseous sarcomas 90 85 93 75 69 80 70 64 76 69 63 74
a. Rhabdomyosarcomas 92 85 96 74 65 81 69 60 77 68 59 76
d. Other specified soft tissue sarcomas 87 77 93 75 64 84 71Note E: Use with caution 60 80 68Note E: Use with caution 56 77
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 92 86 96 91 85 95 91 85 95 91 85 95
b. Malignant extracranial and extragonadal germ cell tumours 91 75 97 91 75 97 91 75 97 91 75 97
c. Malignant gonadal germ cell tumours 97 83 100 97 83 100 97 83 100 97 83 100
XI. Other malignant epithelial neoplasms and malignant melanomas 96 92 98 93 88 96 92 86 95 91 86 94
b. Thyroid carcinomas 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period 100 Note ..: not available for a specific reference period Note ..: not available for a specific reference period
f. Other and unspecified carcinomas 97 90 99 92 84 97 88 78 94 86 74 93
XII. Other and unspecified malignant neoplasms 80Note E: Use with caution 55 92 80Note E: Use with caution 55 92 80Note E: Use with caution 55 92 80Note E: Use with caution 55 92

.. not available for a specific reference period
E Use with caution
Notes: OSP = observed survival proportion; CI = confidence interval; CNS = central nervous system. Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry. All estimates are based on invasive behaviour cases only. The use of caution is suggested in the interpretation of estimates associated with an unrounded standard error > 0.05 and ≤ 0.10.
Source: Statistics Canada, Canadian Cancer Registry death linked file (1992 to 2017).

More information

ISSN: 1209-1367

Note of appreciation

Canada owes the success of its statistical system to a long-standing partnership between Statistics Canada, the citizens of Canada, its businesses, governments and other institutions. Accurate and timely statistical information could not be produced without their continued co-operation and goodwill.

Standards of service to the public

Statistics Canada is committed to serving its clients in a prompt, reliable and courteous manner. To this end, the Agency has developed standards of service which its employees observe in serving its clients.

Copyright

Published by authority of the Minister responsible for Statistics Canada.

© Her Majesty the Queen in Right of Canada as represented by the Minister of Industry, 2021

All rights reserved. Use of this publication is governed by the Statistics Canada Open Licence Agreement.

Catalogue no. 82-003-X

Frequency: Monthly

Ottawa

Report a problem on this page

Is something not working? Is there information outdated? Can't find what you're looking for?

Please contact us and let us know how we can help you.

Privacy notice

Date modified: